Purpose: Blood group B kidney transplant candidates have lower transplantation rates and longer waiting times compared to other blood groups. Kidney transplantation from blood group A2-to-B has offered a solution for these patients. This study aimed to investigate the impact of Basiliximab and Alemtuzumab induction therapies on kidney function and de novo donor-specific antibodies (DSA) in blood type A2-to-B kidney transplant recipients within the first 12 months of post-transplant.
Methods: A retrospective analysis was conducted on 110 consecutive A2-to-B kidney transplant recipients between January 2015 and December 2022. Of these, 46 (41.8%) received Basiliximab, while 64 (58.2%) received Alemtuzumab as induction therapy. Demographics and comorbidities data were collected and compared between the two groups. Serum samples collected at 4- and 12-month intervals post-transplant were used to assess the presence of de novo DSA. Kidney allograft function was evaluated by monitoring serum creatinine levels and assessing Creatinine Clearance based on 24-h urine collection at various time points.
Results: During the follow-up period, 20.00% of patients who received Alemtuzumab developed de novo DSA, whereas none of the patients induced with Basiliximab developed de novo DSA (p = 0.038). Recipients who received Basiliximab were older (mean age = 72.00) and received higher Kidney Donor Profile Index (KDPI) kidneys (mean = 75) compared to those induced with Alemtuzumab (mean age = 58.00, mean KDPI = 49) (p < 0.001), with no significant difference observed in the last follow-up creatinine clearance or creatinine levels between the two groups (p = 0.28).
Conclusion: The use of Basiliximab as induction immunosuppression in A2-to-B kidney transplant recipients is associated with a lower incidence of de novo HLA DSA formation without significant differences in overall renal function compared to Alemtuzumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.trim.2023.101958 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis.
Front Immunol
January 2025
Department of Neurosciences, University of Padua, Padua, Italy.
Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published.
View Article and Find Full Text PDFAlemtuzumab Associated With Higher Mortality Than Basiliximab in Older Kidney Transplant Recipients.
J Surg Res
December 2024
Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Introduction: Kidney transplantation (KT) in older age is increasingly common as more elderly patients live with end-stage renal disease. Immunosuppression (IS) after KT confers additional risk in aging patients with weakened immune systems. We hypothesized that 1-year mortality among KT recipients aged 70 y and older would be higher in those receiving induction IS with alemtuzumab lymphocyte depletion versus basiliximab interleukin-2 inhibition.
View Article and Find Full Text PDFOutcomes of Older Primary Kidney Transplant Recipients by Induction Agent and High-risk Viral Discordance Status in the United States.
Transplant Direct
October 2024
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN.
Article Synopsis
- The study investigates how the type of induction therapy and high-risk viral discordance affect outcomes in kidney transplant recipients over the age of 55.
- It analyzes data from over 87,000 transplant cases between 2005 and 2022, focusing on three induction types: rabbit antithymocyte globulin (r-ATG), interleukin-2 receptor antagonist (IL-2RA), and alemtuzumab.
- Results indicate that while induction type didn't impact recipient survival, high-risk Epstein-Barr virus discordance increased mortality, and alemtuzumab was linked to a higher risk of graft loss compared to r-ATG.
Rapamycin Prevents Expansion of Costimulation Blockade-resistant CD8+ Alloreactive Memory Cells following Depletional Induction in Renal Transplant Recipients.
J Immunol
November 2024
Department of Surgery, Duke University School of Medicine, Durham, NC.
Alemtuzumab induction with belatacept/rapamycin-based maintenance immunotherapy (ABR) prevents kidney allograft rejection and specifically limits early costimulation blockade-resistant rejection (CoBRR). To evaluate the mechanisms by which this regimen alters CoBRR, we characterized the phenotype and functional response of preexisting memory cells to allogeneic endothelial cells using intracellular cytokine staining and flow cytometry. IL-7-induced lymphocyte proliferation in the presence or absence of rapamycin was assessed to characterize the phenotype of proliferating cells.
View Article and Find Full Text PDFOcrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
Mult Scler
August 2024
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Background: The reason why some multiple sclerosis (MS) patients show disease activity after alemtuzumab (ALM) is still unclear, but ocrelizumab (OCR) could represent an interesting sequential therapeutic approach.
Objectives: To investigate safety and efficacy of OCR in MS patients with disease activity after two ALM courses.
Methods: Observational retrospective multi-centers Italian cohort study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!